Phio Announces Positive New Data Validating the INTASYL™ Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth
Phio Pharmaceuticals Corp. on 6ix
Earlier from Phio Pharmaceuticals
- Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
- Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene
- Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering
- Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
- Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements
Later from Phio Pharmaceuticals
- Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
- Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
- Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
- Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Follow Phio Pharmaceuticals into a list and get an email when it puts out news.
Follow Phio Pharmaceuticals